Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti-PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial

J Clin Oncol. 2022 May 10;40(14):1596-1597. doi: 10.1200/JCO.21.02904. Epub 2022 Mar 8.

Authors

Timothée Olivier¹, Vinay Prasad¹

Affiliation

¹ Timothée Olivier, MD, Department of Oncology, Geneva University Hospital, Geneva, Switzerland, Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA; and Vinay Prasad, MD, MPH, Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA.

PMID: 35258990
DOI: 10.1200/JCO.21.02904

No abstract available

Publication types

Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Immunotherapy
Ipilimumab / adverse effects
Melanoma* / drug therapy
Melanoma* / pathology
Skin Neoplasms* / drug therapy

Substances

Ipilimumab